InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,673.60
(
0.16%
)
Dow Jones
39,308.00
(
0.00%
)
Brent Oil
87.04
(
-0.34%
)
Bitcoin
55,342.67
(
-2.87%
)
Post# of 252487
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225327

Monday, 07/15/2019 5:14:08 PM

Monday, July 15, 2019 5:14:08 PM

Post# of 252487
ABUS reports phase-1b HBV data for AB-506:

https://finance.yahoo.com/news/arbutus-announces-preliminary-phase-1a-200500198.html

Mean HBV DNA and HBV RNA decreases at Day 28 (end of treatment) ranged from -2.0 log (160mg dose) to -2.8 log (400mg dose) and -2.4 log (for both doses), respectively…

These log-reduction-in viral-load numbers seem a little low for 28 days of treatment.

ABUS’ AB-506 works by the same MoA as ENTA’s EDP-514 (#msg-149794330). ASMB has one too (#msg-148672065).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up